APP and neurodegenerative disease: The immunomodulatory effect of BS-I in APP/PS1 mice indicates the therapeutic potential of this drug for AD, because neuro-inflammation is a critical risk factor for neurodegenerative disease, and the modulation of the immune system is widely accepted to be able to influence disease progression.